Pages that link to "Q43687803"

The following pages link to Tumor necrosis factor-related apoptosis-inducing ligand and chemotherapy cooperate to induce apoptosis in mesothelioma cell lines (Q43687803):

Displaying 36 items.

• Doxorubicin increases the effectiveness of Apo2L/TRAIL for tumor growth inhibition of prostate cancer xenografts (Q24793079) (← links)
• The anti-tumor effect of Apo2L/TRAIL on patient pancreatic adenocarcinomas grown as xenografts in SCID mice (Q24811656) (← links)
• Cyclophosphamide chemotherapy sensitizes tumor cells to TRAIL-dependent CD8 T cell-mediated immune attack resulting in suppression of tumor growth (Q33502208) (← links)
• Multifunctional Chitosan Magnetic-Graphene (CMG) Nanoparticles: a Theranostic Platform for Tumor-targeted Co-delivery of Drugs, Genes and MRI Contrast Agents (Q33678931) (← links)
• Systemic but not topical TRAIL-expressing mesenchymal stem cells reduce tumour growth in malignant mesothelioma (Q33834736) (← links)
• Valproic acid, an antiepileptic drug with histone deacetylase inhibitory activity, potentiates the cytotoxic effect of Apo2L/TRAIL on cultured thoracic cancer cells through mitochondria-dependent caspase activation (Q35082212) (← links)
• Cellular FLICE-inhibitory protein: an attractive therapeutic target? (Q35186676) (← links)
• Defective core-apoptosis signalling in diffuse malignant pleural mesothelioma: opportunities for effective drug development (Q35789268) (← links)
• Human agonistic TRAIL receptor antibodies Mapatumumab and Lexatumumab induce apoptosis in malignant mesothelioma and act synergistically with cisplatin. (Q36259724) (← links)
• The role of the mitochondria in mediating cytotoxicity of anti-cancer therapies (Q36733723) (← links)
• Mammalian target of rapamycin contributes to the acquired apoptotic resistance of human mesothelioma multicellular spheroids (Q36741548) (← links)
• Novel Anticancer Platinum(IV) Complexes with Adamantylamine: Their Efficiency and Innovative Chemotherapy Strategies Modifying Lipid Metabolism (Q37139330) (← links)
• Novel Targeted Therapies and Vaccination Strategies for Mesothelioma (Q37855667) (← links)
• Physiological and molecular effects of Apo2L/TRAIL and cisplatin in ovarian carcinoma cell lines (Q38358514) (← links)
• Alpha-tocopheryl succinate and TRAIL selectively synergise in induction of apoptosis in human malignant mesothelioma cells (Q38798516) (← links)
• Antitumor effects of TRAIL-expressing mesenchymal stromal cells in a mouse xenograft model of human mesothelioma (Q38927008) (← links)
• Sialic acid-binding lectin (leczyme) induces apoptosis to malignant mesothelioma and exerts synergistic antitumor effects with TRAIL. (Q39050974) (← links)
• Corosolic acid triggers mitochondria and caspase-dependent apoptotic cell death in osteosarcoma MG-63 cells (Q39588134) (← links)
• Doxorubicin and etoposide sensitize small cell lung carcinoma cells expressing caspase-8 to TRAIL. (Q39711397) (← links)
• mTOR mediates survival signals in malignant mesothelioma grown as tumor fragment spheroids (Q39977210) (← links)
• Cisplatin enhances the antitumor effect of tumor necrosis factor-related apoptosis-inducing ligand gene therapy via recruitment of the mitochondria-dependent death signaling pathway (Q40007577) (← links)
• Rapid and profound potentiation of Apo2L/TRAIL-mediated cytotoxicity and apoptosis in thoracic cancer cells by the histone deacetylase inhibitor Trichostatin A: the essential role of the mitochondria-mediated caspase activation cascade (Q40202606) (← links)
• Development of resistance to chemotherapeutic drugs in human osteosarcoma cell lines largely depends on up-regulation of Clusterin/Apolipoprotein J. (Q40209979) (← links)
• Essential role of c-Jun-NH2-terminal kinase on synergy induction of apoptosis by TRAIL plus ADM in ADM resistant MCF-7/ADM cells (Q40279465) (← links)
• Time sequence of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and cisplatin treatment is responsible for a complex pattern of synergistic cytotoxicity (Q40309194) (← links)
• Bid mediates apoptotic synergy between tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and DNA damage. (Q40477763) (← links)
• FLIP overexpression inhibits death receptor-induced apoptosis in malignant mesothelial cells (Q40521494) (← links)
• Combination of TRAIL gene therapy and chemotherapy enhances antitumor and antimetastasis effects in chemosensitive and chemoresistant breast cancers. (Q40639389) (← links)
• Cell cycle checkpoint status in human malignant mesothelioma cell lines: response to gamma radiation. (Q42560724) (← links)
• A novel in vitro model of human mesothelioma for studying tumor biology and apoptotic resistance (Q42575346) (← links)
• Resistance of prostate cancer cells to soluble TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) can be overcome by doxorubicin or adenoviral delivery of full-length TRAIL. (Q43696432) (← links)
• c-Jun N-terminal kinase contributes to apoptotic synergy induced by tumor necrosis factor-related apoptosis-inducing ligand plus DNA damage in chemoresistant, p53 inactive mesothelioma cells (Q44411415) (← links)
• Etoposide upregulates Bax-enhancing tumour necrosis factor-related apoptosis inducing ligand-mediated apoptosis in the human hepatocellular carcinoma cell line QGY-7703. (Q44489218) (← links)
• Death receptor 5 and Bcl-2 protein expression as predictors of tumor response to gemcitabine and cisplatin in patients with advanced non-small-cell lung cancer (Q44723249) (← links)
• Suppression of pancreatic tumor growth in the liver by systemic administration of the TRAIL gene driven by the hTERT promoter (Q45108559) (← links)
• Clinical and biologic prognostic factors in malignant pleural mesothelioma (Q50050310) (← links)